Login Register Cart 0
Generic placeholder image

Current Psychiatry Research and Reviews

Editor-in-Chief

ISSN (Print): 2666-0822
ISSN (Online): 2666-0830

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Psychopharmacological Treatment of Depression and Anxiety and their Different Drug Delivery Targets

Author(s): Aditya Sharma, Md. Aftab Alam*, Awaneet Kaur, Shaweta Sharma and Shikha Yadav

Volume 20, Issue 4, 2024

Published on: 11 October, 2023

Page: [297 - 322] Pages: 26

DOI: 10.2174/2666082219666230822140902

Price: $65

Abstract

General practitioners observe a high prevalence of anxiety and depression symptoms. Depressed or anxious patients frequently develop both conditions. The symptoms of both diseases may be present at the same time. There has been numerous studies on higher levels of depression, bipolar disorder II, and mixed depression. So, we ended up reviewing different drug delivery targets. Even at low dosages, antidepressants were better absorbed and were more effective when given by the nose. In this review, we focused on cutting-edge methods for intranasal antidepressant delivery vehicles. Consequently, it seems that drugs that are sufficiently effective, have fewer side effects, and are less expensive. The researchers in this metaanalysis set out to determine whether or not they have been used successfully in traditional medicine to treat depression in human or animal studies.

« Previous Next »
Graphical Abstract

[1]
Correll CU, Solmi M, Cortese S, et al. The future of psychopharmacology: A critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry 2023; 22(1): 48-74.
[http://dx.doi.org/10.1002/wps.21056 ] [PMID: 36640403]
[2]
Jha MK, Mathew SJ. Pharmacotherapies for treatment-resistant depression: How antipsychotics fit in the rapidly evolving therapeutic landscape. Am J Psychiatry 2023; 180(3): 190-9.
[http://dx.doi.org/10.1176/appi.ajp.20230025 ] [PMID: 36855876]
[3]
Rothschild AJ. Can psychopharmacology do more for our patients with anosognosia? J Clin Psychopharmacol 2023; 43(3): 197-9.
[http://dx.doi.org/10.1097/JCP.0000000000001687] [PMID: 37126825]
[4]
Sadeghi MA, Nassireslami E, Yousefi Zoshk M, Hosseini Y, Abbasian K, Chamanara M. Phosphodiesterase inhibitors in psychiatric disorders. Psychopharmacology 2023; 240(6): 1201-19.
[http://dx.doi.org/10.1007/s00213-023-06361-3] [PMID: 37060470]
[5]
Emtyazi D. Studying the effects of focused ultrasound-triggered drug delivery and deep brain stimulation on post-traumatic stress disorder-type behaviour Doctoral dissertation, University of Toronto (Canada) 2023.
[6]
Viguera AC, Freeman MP, Kobylski LA, et al. Risk of major malformations following first-trimester exposure to olanzapine. J Clin Psychopharmacol 2023; 43(2): 106-12.
[http://dx.doi.org/10.1097/JCP.0000000000001665] [PMID: 36825887]
[7]
Weiss B, Ginige I, Shannon L, et al. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychol Med 2023; 54(1): 178-92.
[PMID: 37264814]
[8]
Vlcek P, Bob P, Vales K. Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression? J Psychopharmacol 2023; 37(11): 1157-60.
[http://dx.doi.org/10.1177/02698811231179808] [PMID: 37300415]
[9]
Pinna G. Biomarkers and treatments for mood disorders encompassing the neurosteroid and endocannabinoid systems. J Neuroendocrinol 2023; 35(2): e13226.
[http://dx.doi.org/10.1111/jne.13226] [PMID: 36625096]
[10]
Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM. The need for establishing best practices and gold standards in psychedelic medicine. J Affect Disord 2023; 332: 47-54.
[http://dx.doi.org/10.1016/j.jad.2023.03.083 ] [PMID: 37003433]
[11]
Gonda X, Dome P, Neill JC, Tarazi FI. Novel antidepressant drugs: Beyond monoamine targets. CNS Spectr 2023; 28(1): 6-15.
[http://dx.doi.org/10.1017/S1092852921000791] [PMID: 34588093]
[12]
Volkow ND, Blanco C. Substance use disorders: A comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry 2023; 22(2): 203-29.
[http://dx.doi.org/10.1002/wps.21073 ] [PMID: 37159360]
[13]
Herrera-Imbroda J. Changing the paradigm in treatment-resistant depression: A review of long-term efficacy and tolerability of esketamine nasal spray. Exp Clin Psychopharmacol 2023.
[http://dx.doi.org/10.1037/pha0000650 ] [PMID: 37126036]
[14]
Ponomarenko P, Seragnoli F, Calder A, Oehen P, Hasler G. Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors. J Psychopharmacol 2023; 37(7): 660-78.
[http://dx.doi.org/10.1177/02698811231155117] [PMID: 36855289]
[15]
Kodali M, Jankay T, Shetty AK, Reddy DS. Pathophysiological basis and promise of experimental therapies for Gulf War Illness, a chronic neuropsychiatric syndrome in veterans. Psychopharmacology 240(4): 673-97.
[http://dx.doi.org/10.1007/s00213-023-06319-5] [PMID: 36790443]
[16]
Belge JB, Sabbe AC, Sabbe BG. An update on pharmacotherapy for recurrent depression in 2022. Expert Opin Pharmacother 2022; 24(12): 1387-94.
[17]
Ge J, Tan R, Gao Q, et al. A multifunctional nanocarrier system for highly efficient and targeted delivery of ketamine to NMDAR sites for improved treatment of depression. Adv Healthc Mater 2023; 2300154.
[http://dx.doi.org/10.1002/adhm.202300154 ] [PMID: 37031162]
[18]
Montazersaheb S, Soofiyani SR, Nakhlband A, Farahzadi R, Saeedi N, Barzegar H. Bidirectional relations between anxiety, depression, and cancer: A review. Curr Drug Targets 2023; 24(2): 118-30.
[http://dx.doi.org/10.2174/1389450123666220922094403] [PMID: 36154570]
[19]
Han B, Pan Y, Li H. Recent research advancements in interventions and assessments related to chronic obstructive pulmonary disease rehabilitation. J Biomed Nanotechnol 2023; 19(2): 228-33.
[http://dx.doi.org/10.1166/jbn.2023.3532]
[20]
Antunes JL, Amado J, Veiga F, Paiva-Santos AC, Pires PC. Nanosystems, drug molecule functionalization and intranasal delivery: an update on the most promising strategies for increasing the therapeutic efficacy of antidepressant and anxiolytic drugs. Pharmaceutics 2023; 15(3): 998.
[http://dx.doi.org/10.3390/pharmaceutics15030998] [PMID: 36986859]
[21]
Wu S, Chen Z, Xuan Z, et al. Serum-derived exosomes of patients with depression with increased miR-96-5p inhibit neuronal differentiation by targeting RAC1. J Biomed Nanotechnol 2023; 19(1): 54-64.
[http://dx.doi.org/10.1166/jbn.2023.3527]
[22]
Wang Z, Gonzalez KM, Cordova LE, Lu J. Nanotechnology-empowered therapeutics targeting neurodegenerative diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2023; •••: e1907.
[http://dx.doi.org/10.1002/wnan.1907 ] [PMID: 37248794]
[23]
Ferreira JP, Di Bella D, Andreotti DZ, et al. Gold nanoparticles improve clinical parameters and reduce neurological alterations in sepsis-induced mice. J Biomed Nanotechnol 2023; 19(1): 182-93.
[http://dx.doi.org/10.1166/jbn.2023.3502]
[24]
Zhu T, Wang H, Gu H, et al. Melanin-like polydopamine nanoparticles mediating anti-inflammatory and rescuing synaptic loss for inflammatory depression therapy. J Nanobiotechnology 2023; 21(1): 52.
[http://dx.doi.org/10.1186/s12951-023-01807-4] [PMID: 36765377]
[25]
Naderi MJ, Mahmoudi A, Kesharwani P, Jamialahmadi T, Sahebkar A. Recent advances of nanotechnology in the treatment and diagnosis of polycystic ovary syndrome. J Drug Deliv Sci Technol 2023; 79: 104014.
[26]
Nano-Hydrogel YL. Treatment of depression and epilepsy. J Biomed Nanotechnol 2022; 18(4): 1097-105.
[http://dx.doi.org/10.1166/jbn.2022.3318 ] [PMID: 35854439]
[27]
Nevins S, McLoughlin CD, Oliveros A, et al. Nanotechnology approaches for prevention and treatment of chemotherapy-induced neurotoxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors. Small 2023; 14: e2300744.
[http://dx.doi.org/10.1002/smll.202300744 ] [PMID: 37058079]
[28]
Zhou Z, Zhou Y, Huang Z, et al. Notopterol improves cognitive dysfunction and depression-like behavior via inhibiting STAT3/NF-ĸB pathway mediated inflammation in glioma-bearing mice. Int Immunopharmacol 2023; 118: 110041.
[http://dx.doi.org/10.1016/j.intimp.2023.110041] [PMID: 37004346]
[29]
Pires PC, Paiva-Santos AC, Veiga F. Nano and microemulsions for the treatment of depressive and anxiety disorders: An efficient approach to improve solubility, brain bioavailability and therapeutic efficacy. Pharmaceutics 2022; 14(12): 2825.
[http://dx.doi.org/10.3390/pharmaceutics14122825] [PMID: 36559318]
[30]
Manocha S, Dhiman S, Grewal AS, Guarve K. Nanotechnology: An approach to overcome bioavailability challenges of nutraceuticals. J Drug Deliv Sci Technol 2022; 72: 103418.
[http://dx.doi.org/10.1016/j.jddst.2022.103418]
[31]
Zhu C, Zhang T, Li Q, Chen X, Wang K. Depression and anxiety during the COVID-19 pandemic: Epidemiology, mechanism, and treatment. Neurosci Bull 2023; 39(4): 675-84.
[http://dx.doi.org/10.1007/s12264-022-00970-2] [PMID: 36411394]
[32]
Koller D, Pathak GA, Wendt FR, et al. Epidemiologic and genetic associations of endometriosis with depression, anxiety, and eating disorders. JAMA Netw Open 2023; 6(1): e2251214.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.51214] [PMID: 36652249]
[33]
Ahmad MH, Rizvi MA, Ali M, Mondal AC. Neurobiology of depression in Parkinson’s disease: Insights into epidemiology, molecular mechanisms and treatment strategies. Ageing Res Rev 2023; 85101840.
[http://dx.doi.org/10.1016/j.arr.2022.101840] [PMID: 36603690]
[34]
Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: A systematic review and meta-analysis. JAMA Dermatol 2023; 159(3): 281-8.
[http://dx.doi.org/10.1001/jamadermatol.2022.6085] [PMID: 36696123]
[35]
Knowles SR, Skvarc D, Ford AC, et al. Negative impact of disorders of gut-brain interaction on health-related quality of life: Results from the Rome foundation global epidemiology survey. Gastroenterology 2023; 164(4): 655-668.e10.
[http://dx.doi.org/10.1053/j.gastro.2022.12.009] [PMID: 36565940]
[36]
Lee ARYB, Leong I, Lau G, et al. Depression and anxiety in older adults with cancer: Systematic review and meta-summary of risk, protective and exacerbating factors. Gen Hosp Psychiatry 2023; 81: 32-42.
[http://dx.doi.org/10.1016/j.genhosppsych.2023.01.008] [PMID: 36724695]
[37]
Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T. Depression and anxiety in inflammatory bowel disease: Epidemiology, mechanisms and treatment. Nat Rev Gastroenterol Hepatol 2022; 19(11): 717-26.
[http://dx.doi.org/10.1038/s41575-022-00634-6] [PMID: 35732730]
[38]
Saghafian F, Hajishafiee M, Rouhani P, Saneei P. Dietary fiber intake, depression, and anxiety: A systematic review and meta-analysis of epidemiologic studies. Nutr Neurosci 2023; 26(2): 125-08.
[PMID: 36692989]
[39]
Martin P. The epidemiology of anxiety disorders: A review. Dialogues Clin Neurosci 2022; 5(3): 281-98.
[PMID: 22034470]
[40]
Kakhramonovich TP. Epidemiology of pysichiatric disorders. Tex State J Med 2022; 12: 102-5.
[41]
Manjunatha N, Jayasankar P, Rao G, et al. Epidemiology of common mental disorders: Results from “National Mental Health Survey” of India, 2016. Indian J Psychiatry 2022; 64(1): 13-9.
[http://dx.doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_865_21] [PMID: 35400745]
[42]
Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2022.
[PMID: 21485743]
[43]
Zhao Y, Wu X, Tang M, et al. Late-life depression: Epidemiology, phenotype, pathogenesis and treatment before and during the COVID-19 pandemic. Front Psychiatry 2023; 14: 1017203.
[http://dx.doi.org/10.3389/fpsyt.2023.1017203] [PMID: 37091719]
[44]
Wittenborn AK, Lachmar EM, Huerta P, Mitchell EA, Tseng CF. Global epidemiology, etiology, and treatment: Depressive and anxiety disorders across the lifespan. In: Wampler KS, Rastogi M, Singh R, Eds The handbook of systemic family therapy: Systemic family therapy and global health issues. Wiley Blackwell 2020; pp. 245-65.
[45]
Scarella TM, Boland RJ, Barsky AJ. Illness anxiety disorder: Psychopathology, epidemiology, clinical characteristics, and treatment. Psychosom Med 2019; 81(5): 398-407.
[http://dx.doi.org/10.1097/PSY.0000000000000691] [PMID: 30920464]
[46]
Merikangas KR, Nakamura EF, Kessler RC. Epidemiology of mental disorders in children and adolescents. Dialogues Clin Neurosci 2022; 11(1): 7-20.
[PMID: 19432384]
[47]
Avdija A. Substance use and stress-induced cognitive impairment: The causes of anxiety and depression among college students. J Drug Educ 2023; 51(3-4): 70.
[PMID: 36591867]
[48]
Umareta NR. A literature review of depression and anxiety in chronic obstructive pulmonary disease (COPD) patients. Scientia Psychiatrica 2021; 4(1): 339-45.
[http://dx.doi.org/10.37275/scipsy.v4i1.97]
[49]
Zhou X, Yi W, Zhi Y, et al. Stress-activated protein kinase jnk modulates depression-like behaviors in mice. Mol Neurobiol 2023; 60(5): 2367-78.
[http://dx.doi.org/10.1007/s12035-023-03209-x] [PMID: 36650421]
[50]
Belmon AP. Music therapy: A best way to solve anxiety and depression in diabetes mellitus patients. In: Advances in speech and music technology: Computational aspects and applications. Cham: Springer International Publishing 2023; pp. 237-47.
[51]
Zhang LG, Cheng LF, Wang TT, et al. Chain mediating effect of insomnia, depression, and anxiety on the relationship between nightmares and cognitive deficits in adolescents. J Affect Disord 2023; 322: 2-8.
[http://dx.doi.org/10.1016/j.jad.2022.10.047] [PMID: 36343783]
[52]
Haddad M, Boyce P. Fast Facts: Depression. Karger Medical and Scientific Publishers 2023.
[53]
Nigussie K, Sertsu A, Ayana GM, et al. Determinants of depression and anxiety among type 2 diabetes patients in governments’ hospitals at Harari regional state, Eastern Ethiopia: A multi-center cross-sectional study. BMC Psychiatry 2023; 23(1): 13.
[http://dx.doi.org/10.1186/s12888-022-04494-x] [PMID: 36604654]
[54]
Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C. Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. Transl Psychiatry 2023; 13(1): 5.
[http://dx.doi.org/10.1038/s41398-022-02297-y] [PMID: 36624089]
[55]
Yu Y, Liu J, Skokauskas N, et al. Prevalence of depression and anxiety, and associated factors, among Chinese primary and high school students: A cross-sectional, epidemiological study. Asia-Pac Psychiatry 2023; 15(1): e12523.
[http://dx.doi.org/10.1111/appy.12523 ] [PMID: 36596718]
[56]
Marlow M, Skeen S, Grieve CM, et al. Detecting depression and anxiety among adolescents in South Africa: validity of the isiXhosa patient health Questionnaire-9 and generalized anxiety Disorder-7. J Adolesc Health 2023; 72(1): S52-60.
[http://dx.doi.org/10.1016/j.jadohealth.2022.09.013] [PMID: 36274021]
[57]
Zaccarelli-Magalhães J, Abreu GR, Fukushima AR, et al. Postpartum depression in rats causes poor maternal care and neurochemical alterations on dams and long-lasting impairment in sociability on the offspring. Behav Brain Res 2023; 436114082.
[http://dx.doi.org/10.1016/j.bbr.2022.114082] [PMID: 36041571]
[58]
Yadav U, Sharma AK, Patil D. Review of automated depression detection: Social posts, audio and video, open challenges and future direction. Concurr Comput 2023; 35(1): e7407.
[http://dx.doi.org/10.1002/cpe.7407]
[59]
Cai L, He Q, Luo H, et al. Is depression in patients with temporal lobe epilepsy related to hippocampal sclerosis? A meta-analysis. Clin Neurol Neurosurg 2023; 225107602.
[http://dx.doi.org/10.1016/j.clineuro.2023.107602] [PMID: 36689793]
[60]
Zhao Z, Mei X, Shi L, Zheng C. The effect of antidepressant therapy on a patient with progressive supranuclear palsy accompanied by depression, anxiety and fluctuating dementia. Asian J Psychiatr 2023; 80: 103418.
[http://dx.doi.org/10.1016/j.ajp.2022.103418] [PMID: 36565660]
[61]
Kahn RS, Kalus O, Wetzler S, Van Praag HM. The role of serotonin in the regulation of anxiety. In: Role Of Serotonin In Psychiatric Disorders. (1st ed.), Routledge 2023.
[http://dx.doi.org/10.4324/9781315825861-6]
[62]
Karaş H, Küçükparlak İ, Özbek MG, Yılmaz, T. Addictive smartphone use in the elderly: Relationship with depression, anxiety and sleep quality. Psychogeriatrics 2023; 23(1): 116-25.
[http://dx.doi.org/10.1111/psyg.12910] [PMID: 36366976]
[63]
Park H. Neurobiological Aspects of Schizophrenia and Relationship Between Neurological Disorders: Depression, Anxiety, and Epilepsy. Cognizance of Schizophrenia: A Profound Insight into the Psyche 2023; 45-59.
[64]
Bhatt S, Devadoss T, Jha NK, et al. Targeting inflammation: A potential approach for the treatment of depression. Metab Brain Dis 2023; 38(1): 45-59.
[http://dx.doi.org/10.1007/s11011-022-01095-1] [PMID: 36239867]
[65]
Botto R, Callai N, Cermelli A, Causarano L, Rainero I. Anxiety and depression in Alzheimer’s disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline. Neurol Sci 2022; 43(7): 4107-24.
[http://dx.doi.org/10.1007/s10072-022-06068-x] [PMID: 35461471]
[66]
Chen C. Recent advances in the study of the comorbidity of depressive and anxiety disorders. Adv Clin Exp Med 2022; 31(4): 355-8.
[http://dx.doi.org/10.17219/acem/147441] [PMID: 35394125]
[67]
Mai AS, Lim OZH, Ho YJ, et al. Prevalence, risk factors and intervention for depression and anxiety in pulmonary hypertension: A systematic review and meta-analysis. Front Med 2022; 9765461.
[http://dx.doi.org/10.3389/fmed.2022.765461] [PMID: 35252232]
[68]
Mofatteh M. Risk factors associated with stress, anxiety, and depression among university undergraduate students. AIMS Public Health 2021; 8(1): 36-65.
[http://dx.doi.org/10.3934/publichealth.2021004] [PMID: 33575406]
[69]
Lynch CJ, Gunning FM, Liston C. Causes and consequences of diagnostic heterogeneity in depression: paths to discovering novel biological depression subtypes. Biol Psychiatry 2020; 88(1): 83-94.
[http://dx.doi.org/10.1016/j.biopsych.2020.01.012] [PMID: 32171465]
[70]
Capuco A, Urits I, Hasoon J, et al. Current perspectives on gut microbiome dysbiosis and depression. Adv Ther 2020; 37(4): 1328-46.
[http://dx.doi.org/10.1007/s12325-020-01272-7] [PMID: 32130662]
[71]
Wright B, Tindall L, Scott AJ, et al. One session treatment (OST) is equivalent to multi-session cognitive behavioral therapy (CBT) in children with specific phobias (ASPECT): results from a national non-inferiority randomized controlled trial. J Child Psychol Psychiatry 2023; 64(1): 39-49.
[http://dx.doi.org/10.1111/jcpp.13665] [PMID: 35915056]
[72]
Kaidesoja M, Cooper Z, Fordham B. Cognitive behavioral therapy for eating disorders: A map of the systematic review evidence base. Int J Eat Disord 2023; 56(2): 295-313.
[http://dx.doi.org/10.1002/eat.23831] [PMID: 36315392]
[73]
Ando M, Kao YC, Lee YC, et al. Remote cognitive behavioral therapy for older adults with anxiety symptoms: A systematic review and meta-analysis. J Telemed Telecare 2023; 16: 1357633X231151788.
[http://dx.doi.org/10.1177/1357633X231151788]
[74]
Komalasari R. Treatment of menstrual discomfort in young women and a cognitive behavior therapy (CBT) program. In: Perspectives on Coping Strategies for Menstrual and Premenstrual Distress. IGI Global 2023; pp. 194-211.
[http://dx.doi.org/10.4018/978-1-6684-5088-8.ch011]
[75]
Bernstein EE, Phillips KA, Greenberg JL, Curtiss J, Hoeppner SS, Wilhelm S. Mechanisms of cognitive-behavioral therapy effects on symptoms of body dysmorphic disorder: A network intervention analysis. Psychol Med 2023; 53(6): 2531-9.
[http://dx.doi.org/10.1017/S0033291721004451] [PMID: 37310300]
[76]
Lopes FM, Fritzen BH, Antunes GT, Marcondes MV, Mendonça BTV, Dias NM. Articulation of cognitive-behavioral therapy and neuropsychology: A scoping review. Appl Neuropsychol Adult 2023; 1-12.
[http://dx.doi.org/10.1080/23279095.2023.2215890] [PMID: 37232178]
[77]
Katajavuori N, Vehkalahti K, Asikainen H. Promoting university students’ well-being and studying with an acceptance and commitment therapy (ACT)-based intervention. Curr Psychol 2023; 42(6): 4900-12.
[http://dx.doi.org/10.1007/s12144-021-01837-x]
[78]
Wright SR, Graham CD, Houghton R, Ghiglieri C, Berry E. Acceptance and commitment therapy (ACT) for caregivers of children with chronic conditions: A mixed methods systematic review (MMSR) of efficacy, process, and acceptance. J Contextual Behav Sci 2023; 27: 72-97.
[http://dx.doi.org/10.1016/j.jcbs.2022.12.003]
[79]
Klimczak KS, San Miguel GG, Mukasa MN, Twohig MP, Levin ME. A systematic review and meta-analysis of self-guided online acceptance and commitment therapy as a transdiagnostic self-help intervention. Cogn Behav Ther 2023; 52(3): 269-94.
[http://dx.doi.org/10.1080/16506073.2023.2178498] [PMID: 36847182]
[80]
Ma TW, Yuen ASK, Yang Z. The efficacy of acceptance and commitment therapy for chronic pain: A systematic review and meta-analysis. Clin J Pain 2023; 39(3): 147-57.
[http://dx.doi.org/10.1097/AJP.0000000000001096] [PMID: 36827194]
[81]
Koszycki D, Taljaard M, Kogan C, Bradwejn J, Grimes D. Interpersonal psychotherapy for depression in Parkinson’s disease: A feasibility study. J Geriatr Psychiatry Neurol 2023; 36(1): 52-62.
[http://dx.doi.org/10.1177/08919887221090220] [PMID: 35446178]
[82]
Swartz HA, Bylsma LM, Fournier JC, et al. Randomized trial of brief interpersonal psychotherapy and cognitive behavioral therapy for depression delivered both in-person and by telehealth. J Affect Disord 2023; 333: 543-52.
[http://dx.doi.org/10.1016/j.jad.2023.04.092] [PMID: 37121279]
[83]
Abujilban S, Al-Omari H, Issa E, et al. Effectiveness of telephone-based interpersonal psychotherapy on antenatal depressive symptoms: A prospective randomized controlled trial in The Kingdom of Jordan. J Am Psychiatr Nurses Assoc 2023; 30(3): 635-45.
[http://dx.doi.org/10.1177/10783903231171595] [PMID: 37148251]
[84]
Fleck MP, Spanemberg L, de Souza LH, Salum Junior GA. Grief, interpersonal disputes and role transitions: the breadth of Interpersonal Telepsychotherapy as a strategy to reduce mental health suffering due to the COVID-19 pandemic in health professionals. Br J Psychiatry 2023; 45(2): 197-8.
[http://dx.doi.org/10.47626/1516-4446-2022-2867] [PMID: 36574464]
[85]
Valverde N, Mollejo E, Legarra L, Gómez-Gutiérrez M. Psychodynamic psychotherapy for postpartum depression: A systematic review. Matern Child Health J 2023; 27(7): 1156-64.
[http://dx.doi.org/10.1007/s10995-023-03655-y] [PMID: 37029894]
[86]
MacKean M, Lecchi T, Mortimer R, Midgley N. ‘I’ve started my journey to coping better’: exploring adolescents’ journeys through an internet-based psychodynamic therapy (I-PDT) for depression. J Child Psychother 2023; 1-22.
[http://dx.doi.org/10.1080/0075417X.2023.2173271]
[87]
Daniëls M, Van HL, van den Heuvel B, et al. Individual psychotherapy for cluster-C personality disorders: Protocol of a pragmatic RCT comparing short-term psychodynamic supportive psychotherapy, affect phobia therapy and schema therapy (I-FORCE). Trials 2023; 24(1): 260.
[http://dx.doi.org/10.1186/s13063-023-07136-z] [PMID: 37020251]
[88]
Ivey G, Denmeade L. Trainee psychologists’ experiences of learning and conducting psychodynamic therapy via telepsychology. Psychoanal Psychother 2023; 37(2): 155-78.
[http://dx.doi.org/10.1080/02668734.2022.2158210]
[89]
Li J, Li C, Puts M, et al. Effectiveness of mindfulness-based interventions on anxiety, depression, and fatigue in people with lung cancer: A systematic review and meta-analysis. Int J Nurs Stud 2023; 140104447.
[http://dx.doi.org/10.1016/j.ijnurstu.2023.104447] [PMID: 36796118]
[90]
Kahlmann V, Moor CC, van Helmondt SJ, et al. Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): A randomised controlled trial. Lancet Respir Med 2023; 11(3): 265-72.
[http://dx.doi.org/10.1016/S2213-2600(22)00387-3] [PMID: 36427515]
[91]
Leng LL, Yin XC, Ng SM. Mindfulness-based intervention for treating and preventing perinatal depression and anxiety: A systematic review and meta-analysis of randomized controlled trial. Compr Psychiatry 2023; 122: 152375.
[http://dx.doi.org/10.1016/j.comppsych.2023.152375] [PMID: 36841089]
[92]
Interian A, Miller RB, Hill LMS, et al. A pilot study of telehealth mindfulness-based cognitive therapy for depression in parkinson’s disease. J Geriatr Psychiatry Neurol 2023; 36(2): 143-54.
[http://dx.doi.org/10.1177/08919887221103579] [PMID: 35603772]
[93]
Shi R. Mindfulness-based therapy in patients with breast cancer with depression and anxiety: A literature review. highlights in science. Eng Technol 2023; 30: 70-8.
[94]
Pagni BA, Hill E, Walsh MJM, et al. Distinct and shared therapeutic neural mechanisms of mindfulness-based and social support stress reduction groups in adults with autism spectrum disorder. J Psychiatry Neurosci 2023; 48(2): E102-14.
[http://dx.doi.org/10.1503/jpn.220159] [PMID: 36990468]
[95]
Paauw CC, de Roos C, Koornneef MGT, et al. Eye movement desensitization and reprocessing for adolescents with major depressive disorder: Study protocol for a multi-site randomized controlled trial. Trials 2023; 24(1): 206.
[http://dx.doi.org/10.1186/s13063-023-07226-y] [PMID: 36588157]
[96]
Hu S, Ou W, Wang Z, Peng J. Eye movement desensitization and reprocessing versus sertraline in the treatment of depressed adolescents with childhood trauma. Chinese General Practice 2023; 26(06): 692.
[97]
Babaei N, Kerry C, Goode K, et al. Clinical assessment of eye movement desensitization and reprocessing in memory distress: Protocol for a double-blinded randomized controlled trial. JMIR Res Protoc 2023; 12(1): e38552.
[http://dx.doi.org/10.2196/38552] [PMID: 37171869]
[98]
Ghanavatpour A, Marofi M, Kalhor F, Kalhor R. The effect of eye movement desensitization and reprocessing on anxiety and pain after appendectomy in hospitalized children. Evidence Based Care 2023; 12(4): 44-53.
[99]
Yu C, Ruan Y, Sun X, et al. rTMS ameliorates depression/anxiety-like behaviors in experimental autoimmune encephalitis by inhibiting neurotoxic reactive astrocytes. J Affect Disord 2023; 331: 352-61.
[http://dx.doi.org/10.1016/j.jad.2023.03.069] [PMID: 36958487]
[100]
Straeten FA, van Zyl S, Maus B, et al. EXERTION: a pilot trial on the effect of aerobic, smartwatch-controlled exercise on stroke recovery: Effects on motor function, structural repair, cognition, mental well-being, and the immune system. Neurol Res Pract 2023; 5(1): 18.
[http://dx.doi.org/10.1186/s42466-023-00244-w] [PMID: 37170385]
[101]
Sundermann M, Chielli D, Spell S. Nature as medicine: The 7th (Unofficial) Pillar of Lifestyle Medicine. Am J Lifestyle Med 2023; 17(5)
[http://dx.doi.org/10.1177/15598276231174863]
[102]
Zhong Y, Guan J, Ma Y, et al. Role of imaging modalities and N-acetylcysteine treatment in sepsis-associated encephalopathy. ACS Chem Neurosci 2023; 14(11): 2172-82.
[http://dx.doi.org/10.1021/acschemneuro.3c00180] [PMID: 37216423]
[103]
Deleemans JM, Mather H, Spiropoulos A, Toivonen K, Baydoun M, Carlson LE. Recent progress in mind–body therapies in cancer care. Curr Oncol Rep 2023; 25(4): 293-307.
[http://dx.doi.org/10.1007/s11912-023-01373-w] [PMID: 36753025]
[104]
Liu S, Sun Q, Ren X. Novel strategies for cancer immunotherapy: counter-immunoediting therapy. J Hematol Oncol 2023; 16(1): 38.
[http://dx.doi.org/10.1186/s13045-023-01430-8] [PMID: 37055849]
[105]
Sabit H, Kassab A, Alaa D, et al. The effect of probiotic supplementation on the gut–brain axis in psychiatric patients. Curr Issues Mol Biol 2023; 45(5): 4080-99.
[http://dx.doi.org/10.3390/cimb45050260] [PMID: 37232729]
[106]
Kumar A, Pramanik J, Goyal N, et al. Gut microbiota in anxiety and depression: Unveiling the relationships and management options. Pharmaceuticals 2023; 16(4): 565.
[http://dx.doi.org/10.3390/ph16040565] [PMID: 37111321]
[107]
Bhatt S, Kanoujia J, Mohana LS, et al. Role of brain-gut-microbiota axis in depression: Emerging therapeutic avenues. CNS Neurol Disord Drug Targets 2023; 22(2): 276-88.
[http://dx.doi.org/10.2174/1871527321666220329140804]
[108]
Xu T, Cock IE. A review of the sedative, anti-anxiety and immunosti-mulant properties of withania somnifera (L.) dunal (Ashwagandha). Pharmacogn Commun 2023; 13(1): 15-23.
[http://dx.doi.org/10.5530/pc.2023.1.4]
[109]
Wijeweera G, Wijekoon N, Gonawala L, Imran Y, Mohan C, De Silva KRD. Therapeutic implications of some natural products for neuroimmune diseases: A narrative of clinical studies review. Evid Based Complement Alternat Med 2023; 2023: 1-18.
[http://dx.doi.org/10.1155/2023/5583996] [PMID: 37089709]
[110]
Rocha J. Patients’ emotional well being and their cancer prognosis: The interplay and how to optimize patient outcomes by optimizing mental health. Arcadia University 2023.
[111]
Lai JY, Ho JX, Kow ASF, et al. Interferon therapy and its association with depressive disorders – A review. Front Immunol 2023; 14: 1048592.
[http://dx.doi.org/10.3389/fimmu.2023.1048592] [PMID: 36911685]
[112]
Evrensel A. Microbiome-induced autoimmunity and novel therapeutic intervention. Adv Exp Med Biol 2023; 1411: 71-90.
[http://dx.doi.org/10.1007/978-981-19-7376-5_4]
[113]
McCann SR. Art, wine, and medicine. Bone Marrow Transplant 2023; 58(7): 739-41.
[http://dx.doi.org/10.1038/s41409-023-01995-5] [PMID: 37106023]
[114]
Liu M. How yoga influences mental wellness for female college students. journal of education. Int J Educ Hum Soc Sci 2023; 10: 182-90.
[115]
Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol 2022; 49(1): 19-36.
[http://dx.doi.org/10.1111/1346-8138.16207] [PMID: 34709679]
[116]
Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: Towards precision medicine. Nat Rev Drug Discov 2022; 21(3): 224-44.
[http://dx.doi.org/10.1038/s41573-021-00368-1] [PMID: 35039676]
[117]
Selvan P, Hriso C, Mitchell J, Newberg A. Systematic review of yoga for symptom management during conventional treatment of breast cancer patients. Complement Ther Clin Pract 2022; 48: 101581.
[http://dx.doi.org/10.1016/j.ctcp.2022.101581] [PMID: 35398542]
[118]
Marrie RA, Bernstein CN. Psychiatric comorbidity in immune‐mediated inflammatory diseases. World Psychiatry 2021; 20(2): 298-9.
[http://dx.doi.org/10.1002/wps.20873] [PMID: 34002519]
[119]
Zięba A, Matosiuk D, Kaczor AA. The role of genetics in the development and pharmacotherapy of depression and its impact on drug discovery. Int J Mol Sci 2023; 24(3): 2946.
[http://dx.doi.org/10.3390/ijms24032946] [PMID: 36769269]
[120]
Dabrowska J. From recent advances in underlying neurocircuitry of fear and anxiety to promising pharmacotherapies for PTSD: The saga of heart, sex and the developing brain. Neuropharmacology 2023; 23: 2109529.
[http://dx.doi.org/10.1016/j.neuropharm.2023.109529] [PMID: 37004751]
[121]
Madhavan SP. Emerging pharmacotherapy for the treatment of psychological treatment for depression. Eur J Mol Clin Med 2023; 10(1): 2023.
[122]
Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: An overview of systematic reviews. Br J Sports Med 2023; 57(18): 1203-9. bjsports-2022-106195 .
[http://dx.doi.org/10.1136/bjsports-2022-106195] [PMID: 36796860]
[123]
Iseki C. The process of reaching psychological adjustment among adult women diagnosed with metastatic breast cancer and receiving cancer pharmacotherapy. Asia Pac J Oncol Nurs 2023; 10(3): 100184.
[http://dx.doi.org/10.1016/j.apjon.2023.100184] [PMID: 36844250]
[124]
Dunlop BW, Cha J, Choi KS, et al. Shared and unique changes in brain connectivity among depressed patients after remission with pharmacotherapy versus psychotherapy. Am J Psychiatry 2023; 180(3): 218-29.
[http://dx.doi.org/10.1176/appi.ajp.21070727]
[125]
Yoshinaga N, Tanoue H. Mood and anxiety disorders in Japan and cognitive-behavioral therapy. In: Handbook of Cognitive Behavioral Therapy by Disorder. Academic Press 2023; pp. 355-64.
[http://dx.doi.org/10.1016/B978-0-323-85726-0.00034-X]
[126]
Clausen L, Semark BD, Helverskov J, Bulik CM, Petersen LV. Pharmacotherapy in anorexia nervosa: A Danish nation-wide register-based study. J Psychosom Res 2023; 164111077.
[http://dx.doi.org/10.1016/j.jpsychores.2022.111077] [PMID: 36379077]
[127]
Falk A, Joseph R, Smith S, Wilk A. Mood and anxiety disorders: Major depressive disorder. FP Essent 2023; 527: 7-12.
[PMID: 37036766]
[128]
Robberegt SJ, Brouwer ME, Kooiman BEAM, Stikkelbroek YAJ, Nauta MH, Bockting CLH. Meta-analysis: Relapse prevention strategies for depression and anxiety in remitted adolescents and young adults. J Am Acad Child Adolesc Psychiatry 2023; 62(3): 306-17.
[http://dx.doi.org/10.1016/j.jaac.2022.04.014] [PMID: 35513189]
[129]
Albert U, Tomasetti C, Marra C, et al. Treating depression in clinical practice: New insights on the multidisciplinary use of tradozone. Front Psychiatry 2023; 14: 1207621.
[130]
Stein LK, Mayman N, Jette N, Tuhrim S, Dhamoon MS. Risk, determinants, and pharmacologic treatment of depression following acute ischemic stroke. Neurohospitalist 2023; 13(1): 22-30.
[http://dx.doi.org/10.1177/19418744221123199] [PMID: 36531840]
[131]
Gao M, Wu Y, Yang L, et al. Anti-depressant-like effect of fermented Gastrodia elata Bl. by regulating monoamine levels and BDNF/NMDAR pathways in mice. J Ethnopharmacol 2023; 30: 1115832.
[http://dx.doi.org/10.1016/j.jep.2022.115832] [PMID: 36283636]
[132]
Rathod AK, Bapna R, Bundela R, Shukla K. Evaluation of anti-depressant activity on bryophyllum pinnatum leaves. Int J Pharm Sci Res 2023; 8(4): 1-17.
[http://dx.doi.org/10.47760/ijpsm.2023.v08i04.001]
[133]
Tyagi CK. Extraction and evaluation of allium cepa, aloe vera, and butea monosperma for analgesic and anti-depressant properties. J Crit Rev 2020; 7(19): 12521-31.
[134]
Zafar SHA, Farooqui DR, Jawaid I, Afroze S, Karim F, Zafar DSB. Dose-dependent anti-depressant effect of citrus paradisi in rehabilitation of psychological disorders. Pak J Rehabil 2023; 12(1): 99-106.
[http://dx.doi.org/10.36283/pjr.zu.12.1/015]
[135]
Tagra VK, Antal S. Evaluation of anti-depressant potential of boswellic acid in mice. Eur Chem Bull 2023; 12(4): 6484-505.
[136]
Haque E, Ahmed F, Chaurasiya P, Yadav N, Dhiman N, Maity MK. A review on antidepressant effect of herbal drugs. J Pharm Negat Results 2023; 14: 2716-23.
[137]
Amiri MM, Garnida Y, Almulla AF, et al. Herbal therapy for hemorrhoids: An overview of medicinal plants affecting hemorrhoids. Adv Life Sci 2023; 10(1): 22-8.
[138]
Delam H, Keshtkaran Z, Shokrpour N, Eidi A, Bazrafshan MR. The effect of Crocus sativus L. (saffron) herbal tea on happiness in postmenopausal women: A randomized controlled trial. BMC Complementary Medicine and Therapies 2023; 23(1): 176.
[http://dx.doi.org/10.1186/s12906-023-04014-8] [PMID: 37264347]
[139]
Tiwari Y, Morya N, Singh SP, Singh SP. A concise review on versatile medicinal plant achyranthes aspera: traditional use, phytochemistry and pharmacological activities. IJPPR 2023; 14(1): 152-62.
[140]
Gautam A, Pal LC, Rao CV, Kumar V. The role of Indian magical herb selaginella bryopteris L. (Selaginaceae) in pharmacotherapeutic perspective: An overview. Pharmacogn J 2023; 15(1): 14-20.
[http://dx.doi.org/10.5530/pj.2023.15.3]
[141]
Guo J, Fang M, Xiong Z, Zhou K, Zeng P. Mechanistic insights into the anti-depressant effect of curcumin based on network pharmacology and experimental validation. Naunyn Schmiedebergs Arch Pharmacol 2024; 397(1): 583-98.
[http://dx.doi.org/10.1007/s00210-023-02628-w]
[142]
SR Khafaga D. Ewies EF. Drug Delivery Systems Designed to Maximize the Therapeutic Efficacy of Herbal Medication: A Review Article. Egypt J Chem 2023; 66(5): 477-85.
[143]
Moldir Z, Meryuert K, Serik K, et al. Studies on the biological activity of different populations of the medicinal plant rhodiola rosea L. (GOLDEN ROOT). Pak J Bot 2023; 55(5): 1857-65.
[144]
Belge DA, Jeurkar MM. Morphological, pharmacological and toxicological profile of psoralea corylifolia L: A review. IJRAR 2023; 10(2): 146-53.
[145]
Belge DA, Jeurkar MM. Preparing herbal formulations through indigenous and modern methods: An experimental study. J Coast Life Med 2023; 11(1): 902-6.
[146]
Singh LJ, Challam DA, Senjam BD. Medicinal plants as a sources of terpenoids and their impact on Central Nervous System disorders: A review. J Phytopharmacol 2023; 12(2): 104-10.
[http://dx.doi.org/10.31254/phyto.2023.12207]
[147]
Reddy TS, Zomer R, Mantri N. Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. Phytother Res 2023; 37(4): 1526-38.
[http://dx.doi.org/10.1002/ptr.7742] [PMID: 36748949]
[148]
Akanchise T, Angelova A. Potential of nano-antioxidants and nanomedicine for recovery from neurological disorders linked to long COVID syndrome. Antioxidants 2023; 12(2): 393.
[http://dx.doi.org/10.3390/antiox12020393] [PMID: 36829952]
[149]
Cezarotto VS, Franceschi EP, Stein AC, et al. Nanoencapsulation of Vaccinium ashei leaf extract in eudragit® RS100-based nanoparticles increases its in vitro antioxidant and in vivo antidepressant-like actions. Pharmaceuticals 2023; 16(1): 84.
[http://dx.doi.org/10.3390/ph16010084] [PMID: 36678581]
[150]
Kulavi S, Kaur R, Iyer K, Bandyopadhyay J, Sengupta T. A smart & precise approach with nanoparticles-based therapeutic intervention in neurodegenerative diseases. Nanomed J 2023; 10(2): 96-106.
[151]
Mirhadi E, Kesharwani P, Johnston TP, Sahebkar A. Nanomedicine-mediated therapeutic approaches for pulmonary arterial hypertension. Drug Discov Today 2023; 28(6): 103599.
[http://dx.doi.org/10.1016/j.drudis.2023.103599] [PMID: 37116826]
[152]
Singh S, Awasthi R. Breakthroughs and bottlenecks of psoriasis therapy: Emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery. J Drug Deliv Sci Technol 2023; 84: 104548.
[http://dx.doi.org/10.1016/j.jddst.2023.104548]
[153]
Tran KN, Nguyen NPK, Nguyen LTH, Shin HM, Yang IJ. Screening for neuroprotective and rapid antidepressant-like effects of 20 essential oils. Biomedicines 2023; 11(5): 1248.
[http://dx.doi.org/10.3390/biomedicines11051248] [PMID: 37238920]
[154]
Ali J, Baboota S. Nanotechnology-based drug delivery as therapeutic modalities for neurological diseases. Curr Neuropharmacol 2023; 21(3): 491-2.
[http://dx.doi.org/10.2174/1570159X2103230207111522] [PMID: 36960642]
[155]
Khan MS, Mohapatra S, Gupta V, et al. Potential of lipid-based nanocarriers against two major barriers to drug delivery—skin and blood–brain barrier. Membranes 2023; 13(3): 343.
[http://dx.doi.org/10.3390/membranes13030343] [PMID: 36984730]
[156]
Sulakhiya K, Kisku A, Paliwal R, et al. Nanodiagnostics and nanomedicines for neurodegenerative disorders. In: Nanotechnology for Drug Delivery and Pharmaceuticals. Academic Press 2023; pp. 131-63.
[http://dx.doi.org/10.1016/B978-0-323-95325-2.00023-7]
[157]
Xiong RG, Li J, Cheng J, et al. New insights into the protection of dietary components on anxiety, depression, and other mental disorders caused by contaminants and food additives. Trends Food Sci Technol 2023; 138: 44-56.
[http://dx.doi.org/10.1016/j.tifs.2023.06.004]
[158]
Ehsanifar M, Montazeri Z, Zavareh MS, Rafati M, Wang J. Cognitive impairment, depressive-like behaviors and hippocampal microglia activation following exposure to air pollution nanoparticles. Environ Sci Pollut Res Int 2022; 30(9): 23527-37.
[http://dx.doi.org/10.1007/s11356-022-23882-0] [PMID: 36327074]
[159]
Adeyemi SB, Akere AM, Orege JI, Ejeromeghene O, Orege OB, Akolade JO. Polymeric nanoparticles for enhanced delivery and improved bioactivity of essential oils. Heliyon 2023; 9(6): e16543.
[http://dx.doi.org/10.1016/j.heliyon.2023.e16543] [PMID: 37484246]
[160]
Atici T, Bilgi Kamaç M, Yilmaz M, Yilmaz Kabaca A. Zinc oxide nanorod/polymethylene blue (deep eutectic solvent)/gold nanoparticles modified electrode for electrochemical determination of serotonin (5-HT). Electrochim Acta 2023; 458: 142484.
[http://dx.doi.org/10.1016/j.electacta.2023.142484]
[161]
Farajzadeh MA, Barazandeh S, Pezhhanfar S, Afshar MMR. Facile preparation of graphene-modified magnetic nanoparticles and their application in the analysis of four anti-depressant drugs in plasma and urine. ImmunoAnalysis 2023; 3(1): 4.
[http://dx.doi.org/10.34172/ia.2023.04]
[162]
Au A, Mojadadi A, Shao JY, Ahmad G, Witting PK. Physiological benefits of novel selenium delivery via nanoparticles. Int J Mol Sci 2023; 24(7): 6068.
[http://dx.doi.org/10.3390/ijms24076068] [PMID: 37047040]
[163]
Kavitha SK, Mani RK, Shaeena MH. Evaluation of antidepressant activity of solid-lipid nanoparticles using albizzia lebbeck. Eur Chem Bull 2023; 12(5): 4692-702.
[164]
Cordeiro MAG, Sousa Costa A, dos Santos PELH, Santos BK, De Andrade FM. Curcumin nanoformulations and their therapeutic applicability to depressive disorder. Interfaces Científicas - Saúde e Ambiente 2023; 9(2): 57-73.
[http://dx.doi.org/10.17564/2316-3798.2023v9n2p57-73]
[165]
Chen X, Xu L, Chen Q, Su S, Zhuang J, Qiao D. Polystyrene micro- and nanoparticles exposure induced anxiety-like behaviors, gut microbiota dysbiosis and metabolism disorder in adult mice. Ecotoxicol Environ Saf 2023; 259: 115000.
[http://dx.doi.org/10.1016/j.ecoenv.2023.115000] [PMID: 37210994]
[166]
Mohamed ZH, Riyad YM, Hendawy HA, Abdelbary HMH. Enhanced photocatalytic degradation of the antidepressant sertraline in aqueous solutions by zinc oxide nanoparticles. Water 2023; 15(11): 2074.
[http://dx.doi.org/10.3390/w15112074]
[167]
Pawar SD, Gawali K, Kulhari H, Murty US, Kumar P. Amoxapine-loaded solid lipid nanoparticles with superior preclinical pharmacokinetics for better brain delivery: LC-MS/MS and GC-MS analysis. ACS Chem Neurosci 2023; 14(8)
[http://dx.doi.org/10.1021/acschemneuro.2c00673] [PMID: 37027804]
[168]
Ikeda Y, Saigo N, Nagasaki Y. Direct evidence for the involvement of intestinal reactive oxygen species in the progress of depression via the gut-brain axis. Biomaterials 2023; 295: 122053.
[http://dx.doi.org/10.1016/j.biomaterials.2023.122053] [PMID: 36821954]
[169]
Zhou Y, Zhang P, Wang F, et al. Treatment activity of hydrogels loaded with Ba(II) metal-organic frameworks of paroxetine on depression. Sci Adv Mater 2023; 15(3): 400-4.
[http://dx.doi.org/10.1166/sam.2023.4416]
[170]
Hu D, Li T, Liang W, Wang Y, Feng M, Sun J. Silk sericin as building blocks of bioactive materials for advanced therapeutics. J Control Release 2023; 353: 303-16.
[http://dx.doi.org/10.1016/j.jconrel.2022.11.019] [PMID: 36402235]
[171]
Sharma AK. Current trends in nanotheranostics: A concise review on bioimaging and smart wearable technology. Nanotheranostics 2023; 7(3): 258-69.
[http://dx.doi.org/10.7150/ntno.82886] [PMID: 37064611]
[172]
Wang X, Shi G, Fan S, et al. Targeted delivery of food functional ingredients in precise nutrition: design strategy and application of nutritional intervention. Crit Rev Food Sci Nutr 2023; 1-24.
[http://dx.doi.org/10.1080/10408398.2023.2193275] [PMID: 36999956]
[173]
Lee H, Tae G, Hwang S, et al. Heparin-based hydrogel micropatches with human adipose-derived stem cells: A promising therapeutic approach for neuropathic pain relief. Biomedicines 2023; 11(5): 1436.
[http://dx.doi.org/10.3390/biomedicines11051436] [PMID: 37239107]
[174]
Alberto M, Paiva-Santos AC, Veiga F, Pires PC. Lipid and polymeric nanoparticles: Successful strategies for nose-to-brain drug delivery in the treatment of depression and anxiety disorders. Pharmaceutics 2022; 14(12): 2742.
[http://dx.doi.org/10.3390/pharmaceutics14122742] [PMID: 36559236]
[175]
Chen YB, Qiao T, Wang YQ, Cui YL, Wang QS. Hydrogen bond-enhanced nanogel delivery system for potential intranasal therapy of Parkinson’s disease. Mater Des 2022; 219: 110741.
[http://dx.doi.org/10.1016/j.matdes.2022.110741]
[176]
Xu D, Lu YR, Kou N, Hu MJ, Wang QS, Cui YL. Intranasal delivery of icariin via a nanogel-thermoresponsive hydrogel compound system to improve its antidepressant-like activity. Int J Pharm 2020; 586: 119550.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119550] [PMID: 32554031]
[177]
Barbosa AI, Torres T, Lima SAC, Reis S. Hydrogels: A promising vehicle for the topical management of atopic dermatitis. Adv Ther 2021; 4(7): 2100028.
[http://dx.doi.org/10.1002/adtp.202100028]
[178]
Xu D, Qiu C, Wang Y, Qiao T, Cui YL. Intranasal co-delivery of berberine and evodiamine by self-assembled thermosensitive in-situ hydrogels for improving depressive disorder. Int J Pharm 2021; 603: 120667.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120667] [PMID: 33933642]
[179]
Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov 2023; 22(5): 387-409.
[http://dx.doi.org/10.1038/s41573-023-00670-0] [PMID: 36973491]
[180]
Farhangian M, Azarafrouz F, Chavoshinezhad S, Dargahi L. Intranasal interferon-beta alleviates anxiety and depressive-like behaviors by modulating microglia polarization in an Alzheimer’s disease model. Neurosci Lett 2023; 792: 136968.
[http://dx.doi.org/10.1016/j.neulet.2022.136968] [PMID: 36396023]
[181]
Zhou L, Wu X, Qin S, et al. Cell-liposome delivery system based on neuroinflammation to target the amygdala for ameliorating depressive-like behaviors. Int J Pharm 2023; 637: 122724.
[http://dx.doi.org/10.1016/j.ijpharm.2023.122724] [PMID: 36958607]
[182]
Aziz T, Nadeem AA, Sarwar A, et al. Particle nanoarchitectonics for nanomedicine and nanotherapeutic drugs with special emphasis on nasal drugs and aging. Biomedicines 2023; 11(2): 354.
[http://dx.doi.org/10.3390/biomedicines11020354] [PMID: 36830891]
[183]
Amores J. The future of technology for cognitive enhancement and well-being: olfactory wearables. XRDS: Crossroads. ACM Magazine for Students 2023; 29(2): 18-23.
[184]
Joshi K, Pilon D, Shah A, Holiday C, Karkare S, Zhdanava M. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans. J Med Econ 2023; 26(1): 422-9.
[http://dx.doi.org/10.1080/13696998.2023.2188845] [PMID: 36924214]
[185]
Chen X, Hou X, Bai D, et al. Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: A randomized, double-blind, multicenter, active-controlled study conducted in China and USA. Neuropsychiatr Dis Treat 2023; 19: 693-707.
[http://dx.doi.org/10.2147/NDT.S391096] [PMID: 37025256]
[186]
Fuchigami T, Itokazu Y, Morgan JC, Yu RK. Restoration of adult neurogenesis by intranasal administration of gangliosides GD3 and GM1 in the olfactory bulb of A53T alpha-synuclein-expressing parkinson’s-disease model mice. Mol Neurobiol 2023; 60(6): 3329-44.
[http://dx.doi.org/10.1007/s12035-023-03282-2] [PMID: 36849668]
[187]
Yau GTY, Tai W, Arnold JC, Chan HK, Kwok PCL. Cannabidiol for the treatment of brain disorders: Therapeutic potential and routes of administration. Pharm Res 2023; 40(5): 1087-114.
[http://dx.doi.org/10.1007/s11095-023-03469-1] [PMID: 36635488]
[188]
Sharma P, Baisoya D, Chauhan D, Mishra D, Sharma M, Chandra A. Recent progress, therapeutic concepts and pharmaceutical challenges of dendrimer based drug delivery system. J Pharm Negat Results 2023; •••: 6865-73.
[189]
Mahmoud KY, Elhesaisy NA, Rashed AR, et al. Exploring the potential of intranasally administered naturally occurring quercetin loaded into polymeric nanocapsules as a novel platform for the treatment of anxiety. Sci Rep 2023; 13(1): 510.
[http://dx.doi.org/10.1038/s41598-023-27665-6] [PMID: 36627363]
[190]
Nguyen TML, Defaix C, Mendez-David I, et al. Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory/inhibitory synaptic activity. Neuropharmacology 2023; 225: 109357.
[http://dx.doi.org/10.1016/j.neuropharm.2022.109357] [PMID: 36462636]
[191]
Rawal SU, Patel BM, Patel MM. New drug delivery systems developed for brain targeting. Drugs 2022; 82(7): 749-92.
[http://dx.doi.org/10.1007/s40265-022-01717-z] [PMID: 35596879]
[192]
Xu J, Tao J, Wang J. Design and application in delivery system of intranasal antidepressants. Front Bioeng Biotechnol 2020; 8: 626882.
[http://dx.doi.org/10.3389/fbioe.2020.626882] [PMID: 33409272]
[193]
Maffeo NN, Springer CM, Albright JD. A retrospective study on the clinical use and owner perception of venlafaxine efficacy as part of a multimodal treatment for canine fear, anxiety, and aggression. J Vet Behav 2023; 64-65: 54-9.
[http://dx.doi.org/10.1016/j.jveb.2023.06.004]
[194]
Krishnamoorthy B, Raj CN. Preparation and characterization of chitosan coated alginate and carrageenan beads loaded with venlafaxine HCl: A comprehensive study. Int J Pharm Sci Res 2023; 11(1): 41-6.
[http://dx.doi.org/10.26452/ijprls.v11i1.1488]
[195]
Alves C, Tamagno WA, Pompermaier A, Vanin AP, Barcellos LJG. Neurotoxicological effects of venlafaxine on Caenorhabditis elegans and Danio rerio. Comp Biochem Physiol C Toxicol Pharmacol 2023; 271: 109658.
[http://dx.doi.org/10.1016/j.cbpc.2023.109658] [PMID: 37192702]
[196]
Zarowitz BJ, Jain S. Venlafaxine deprescribing and thyroid function. Pharmacotherapy 2023; 43(6): 570-3.
[http://dx.doi.org/10.1002/phar.2803] [PMID: 37052367]
[197]
Tran TTT, Nguyen DM, Dao AQ, Le VT, Vasseghian Y. A state-of-the-art review on the nanomaterial-based sensor for detection of venlafaxine. Chemosphere 2022; 297: 134116.
[http://dx.doi.org/10.1016/j.chemosphere.2022.134116] [PMID: 35227745]
[198]
Zhao Q, Fu B, Lyu N, et al. A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. J Affect Disord 2023; 329: 72-80.
[http://dx.doi.org/10.1016/j.jad.2023.02.067] [PMID: 36813043]
[199]
Shin C, Jeon SW, Lee SH, et al. Efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded 6-week clinical trial. Clin Psychopharmacol Neurosci 2023; 21(1): 135-46.
[http://dx.doi.org/10.9758/cpn.2023.21.1.135] [PMID: 36700320]
[200]
McIntyre RS, Florea I, Pedersen MM, Christensen MC. Head-to-head comparison of vortioxetine versus desvenlafaxine in patients with major depressive disorder with partial response to SSRI therapy. J Clin Psychiatry 2023; 84(4): 47173.
[http://dx.doi.org/10.4088/JCP.23m14780] [PMID: 37227402]
[201]
Bansal R, Hellerstein DJ, Sawardekar S, Chen Y, Peterson BS. A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorder. Psychiatry Res Neuroimaging 2023; 331: 111634.
[http://dx.doi.org/10.1016/j.pscychresns.2023.111634] [PMID: 36996664]
[202]
Feeney A, Papakostas GI. Pharmacotherapy. Psychiatr Clin North Am 2023; 46(2): 277-90.
[http://dx.doi.org/10.1016/j.psc.2023.02.003] [PMID: 37149345]
[203]
Rayburn WF, Albright BB. Completed suicides and intranasal esketamine therapy: A case report and case series. Psychiatry Research Case Reports 2023; 2(1): 100104.
[http://dx.doi.org/10.1016/j.psycr.2023.100104]
[204]
Grossman-Giron A, Maoz H, Nitzan U, et al. Intranasal oxytocin as add-on treatment for inpatients with severe mental illness: a randomized clinical trial. Neuropsychobiology 2023; 82(1): 14-23.
[http://dx.doi.org/10.1159/000528314] [PMID: 36603563]
[205]
Vehlen A, Kellner A, Normann C, Heinrichs M, Domes G. Reduced eye gaze during facial emotion recognition in chronic depression: Effects of intranasal oxytocin. J Psychiatr Res 2023; 159: 50-6.
[http://dx.doi.org/10.1016/j.jpsychires.2023.01.016] [PMID: 36657314]
[206]
Chen Z, Wang Q, Xue X, Huang Z, Wang Y. The neural connections of oxytocin-mediated parental behavior in male mice. Front Mol Neurosci 2023; 161091139.
[http://dx.doi.org/10.3389/fnmol.2023.1091139] [PMID: 36910264]
[207]
Jiang J, Yang M, Tian M, Chen Z, Xiao L, Gong Y. Intertwined associations between oxytocin, immune system and major depressive disorder. Biomed Pharmacother 2023; 163: 114852.
[http://dx.doi.org/10.1016/j.biopha.2023.114852] [PMID: 37163778]
[208]
Rosenblat JD, deVries FE, Doyle Z, et al. A phase II, open-label clinical trial of intranasal ketamine for depression in patients with cancer receiving palliative care (INKeD-PC Study). Cancers 2023; 15(2): 400.
[http://dx.doi.org/10.3390/cancers15020400] [PMID: 36672348]
[209]
Keeler JL, Treasure J, Himmerich H, Brendle M, Moore C, Robison R. Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa. Front Psychiatry 2023; 14: 1181447.
[http://dx.doi.org/10.3389/fpsyt.2023.1181447] [PMID: 37255674]
[210]
Dehestani S, Mohammadpour AH, Sadjadi SA, Sathyapalan T, Sahebkar A. Original article Clinical use of ketamine in psychiatric disorders. Ann Med Psychol 2023; 181(6): 495-508.
[http://dx.doi.org/10.1016/j.amp.2022.05.008]
[211]
Tsang VWL, Tao B, Dames S, Walsh Z, Kryskow P. Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: A retrospective chart review. Ther Adv Psychopharmacol 2023; 13: 20451253231171512.
[http://dx.doi.org/10.1177/20451253231171512] [PMID: 37256163]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy